发布求助
文献互助 智能选刊 最新文献

Journal of Thoracic Oncology最新文献

筛选
英文 中文
66P: Long-term follow-up of limertinib (ASK120067) in patients with locally advanced or metastatic EGFR T790M NSCLC: A multicentre, single-arm, phase IIb study 66P：利莫替尼（ASK120067）对局部晚期或转移性EGFR T790M NSCLC患者的长期随访：一项多中心、单组、IIb期研究
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2025-03-01 DOI: 10.1016/S1556-0864(25)00261-8
L. Wu , B. Li , Y. Fan , Q. Shi , K. Li , J. Fang , G. Chen , Y. Liu , Z. He , Y. Ji , T. Zhou , R. Yang , Z. Li , K. Gu , Y. Pan , Z. Pan , H. Zhang , Y. Bai , D. Jiang , Y-K. Shi
{"title":"66P: Long-term follow-up of limertinib (ASK120067) in patients with locally advanced or metastatic EGFR T790M NSCLC: A multicentre, single-arm, phase IIb study","authors":"L. Wu , B. Li , Y. Fan , Q. Shi , K. Li , J. Fang , G. Chen , Y. Liu , Z. He , Y. Ji , T. Zhou , R. Yang , Z. Li , K. Gu , Y. Pan , Z. Pan , H. Zhang , Y. Bai , D. Jiang , Y-K. Shi","doi":"10.1016/S1556-0864(25)00261-8","DOIUrl":"10.1016/S1556-0864(25)00261-8","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 3","pages":"Pages S51-S52"},"PeriodicalIF":21.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
29P: Evaluation of tusamitamab ravtansine, a CEACAM5-targeting antibody drug conjugate, in non-squamous NSCLC participants with negative or moderate CEACAM5 expression and high circulating CEA: Results from phase II CARMEN-LC06 trial 29P：评估tusamitamab ravtansine（一种靶向CEACAM5的抗体药物偶联物）在CEACAM5阴性或中度表达和高循环CEA的非鳞状NSCLC参与者中的应用：来自II期carmon - lc06试验的结果
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2025-03-01 DOI: 10.1016/S1556-0864(25)00224-2
H. Lena , L. Paz-Ares , H. Harputluoglu , E. Wauters , S. Rossi , M. Ozguroglu , C. Helissey , G. Lo Russo , L. Greillier , M.A.N. Sendur , M. D’Arcangelo , H. Kobayashi , A. Martinez Bueno , O. Ozyilkan , M. Gumus , M. Celanovic , Y. Mekhloufi , E. Nadal
{"title":"29P: Evaluation of tusamitamab ravtansine, a CEACAM5-targeting antibody drug conjugate, in non-squamous NSCLC participants with negative or moderate CEACAM5 expression and high circulating CEA: Results from phase II CARMEN-LC06 trial","authors":"H. Lena , L. Paz-Ares , H. Harputluoglu , E. Wauters , S. Rossi , M. Ozguroglu , C. Helissey , G. Lo Russo , L. Greillier , M.A.N. Sendur , M. D’Arcangelo , H. Kobayashi , A. Martinez Bueno , O. Ozyilkan , M. Gumus , M. Celanovic , Y. Mekhloufi , E. Nadal","doi":"10.1016/S1556-0864(25)00224-2","DOIUrl":"10.1016/S1556-0864(25)00224-2","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 3","pages":"Pages S29-S30"},"PeriodicalIF":21.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
69P: PET/fluorescence dual-modal tracing for targeted inhibition of RRM2 to overcome osimertinib resistance in lung cancer 69P: PET/荧光双峰示踪靶向抑制RRM2克服肺癌中奥西替尼耐药
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2025-03-01 DOI: 10.1016/S1556-0864(25)00264-3
J. Zhu , N. Li
{"title":"69P: PET/fluorescence dual-modal tracing for targeted inhibition of RRM2 to overcome osimertinib resistance in lung cancer","authors":"J. Zhu , N. Li","doi":"10.1016/S1556-0864(25)00264-3","DOIUrl":"10.1016/S1556-0864(25)00264-3","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 3","pages":"Page S53"},"PeriodicalIF":21.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
61P: Response to first-line osimertinib plus pemetrexed/carboplatin in EGFR-mutant advanced NSLCLC with high PDL1 expression 61P：一线奥西替尼加培美曲塞/卡铂对egfr突变的晚期非小细胞肺癌高PDL1表达的疗效
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2025-03-01 DOI: 10.1016/S1556-0864(25)00256-4
C. Weng , Y. Jiao , Q-Q. Tan , J. Liu , H-J. Chen , J-J. Yang
{"title":"61P: Response to first-line osimertinib plus pemetrexed/carboplatin in EGFR-mutant advanced NSLCLC with high PDL1 expression","authors":"C. Weng , Y. Jiao , Q-Q. Tan , J. Liu , H-J. Chen , J-J. Yang","doi":"10.1016/S1556-0864(25)00256-4","DOIUrl":"10.1016/S1556-0864(25)00256-4","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 3","pages":"Pages S48-S49"},"PeriodicalIF":21.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
47P: Efficacy and safety of cadonilimab-based therapies in non-small cell lung cancer patients with progression after immunotherapy 47P：卡多尼莫单抗治疗非小细胞肺癌免疫治疗进展患者的疗效和安全性
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2025-03-01 DOI: 10.1016/S1556-0864(25)00242-4
S. Yu, F. Wu
{"title":"47P: Efficacy and safety of cadonilimab-based therapies in non-small cell lung cancer patients with progression after immunotherapy","authors":"S. Yu, F. Wu","doi":"10.1016/S1556-0864(25)00242-4","DOIUrl":"10.1016/S1556-0864(25)00242-4","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 3","pages":"Pages S40-S41"},"PeriodicalIF":21.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
48P: Real-world evaluation of ipilimumab (Ipi)/nivolumab (Nivo) in combination with two cycles of chemotherapy in patients (pts) with programmed death-ligand (PD-L1) negative advanced non-small cell lung cancer (aNSCLC): Interim results of the RW-9LA study 48P: ipilimumab (Ipi)/nivolumab （Nivo）联合两个周期化疗在程序性死亡配体（PD-L1）阴性晚期非小细胞肺癌（aNSCLC）患者（pts）中的实际评估：RW-9LA研究的中期结果
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2025-03-01 DOI: 10.1016/S1556-0864(25)00243-6
L. Decoster , S. Vande Kerckhove , E. Ravoet , F. Vervenne , K. Vekens
{"title":"48P: Real-world evaluation of ipilimumab (Ipi)/nivolumab (Nivo) in combination with two cycles of chemotherapy in patients (pts) with programmed death-ligand (PD-L1) negative advanced non-small cell lung cancer (aNSCLC): Interim results of the RW-9LA study","authors":"L. Decoster , S. Vande Kerckhove , E. Ravoet , F. Vervenne , K. Vekens","doi":"10.1016/S1556-0864(25)00243-6","DOIUrl":"10.1016/S1556-0864(25)00243-6","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 3","pages":"Page S41"},"PeriodicalIF":21.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
25P: Durvalumab with or without tremelimumab plus chemotherapy as first-line treatment for metastatic NSCLC: Results from the phase III POSEIDON extended China cohort 25P: Durvalumab联合或不联合tremelimumab加化疗作为转移性NSCLC的一线治疗：来自III期POSEIDON扩展中国队列的结果
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2025-03-01 DOI: 10.1016/S1556-0864(25)00220-5
J. Wang , J. Fang , T. Shou , N. Yang , Q. Wang , J. Shi , K. Xiao , W. Zhuang , B. Wang , J. Hu , L. Liu , Y. Yu , Y. Zhang , X. Geng , Y. Zhong , C. Lowery , J. Chen , M.L. Johnson , L. Wang , Z. Chen
{"title":"25P: Durvalumab with or without tremelimumab plus chemotherapy as first-line treatment for metastatic NSCLC: Results from the phase III POSEIDON extended China cohort","authors":"J. Wang , J. Fang , T. Shou , N. Yang , Q. Wang , J. Shi , K. Xiao , W. Zhuang , B. Wang , J. Hu , L. Liu , Y. Yu , Y. Zhang , X. Geng , Y. Zhong , C. Lowery , J. Chen , M.L. Johnson , L. Wang , Z. Chen","doi":"10.1016/S1556-0864(25)00220-5","DOIUrl":"10.1016/S1556-0864(25)00220-5","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 3","pages":"Pages S27-S28"},"PeriodicalIF":21.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
30P: Clinical characteristics and survival outcomes of long-term responders for advanced non-small cell lung cancer patients with first-line PD-1/PD-L1 inhibitors: A multicenter retrospective study 30P：一线PD-1/PD-L1抑制剂治疗晚期非小细胞肺癌患者的临床特征和长期应答者的生存结局：一项多中心回顾性研究
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2025-03-01 DOI: 10.1016/S1556-0864(25)00225-4
Z. Du , X. Ge , Y. Li , Y. Qin , H. Fan , Y. Lv , X. Du , Y. Hu , Z. Liu
{"title":"30P: Clinical characteristics and survival outcomes of long-term responders for advanced non-small cell lung cancer patients with first-line PD-1/PD-L1 inhibitors: A multicenter retrospective study","authors":"Z. Du , X. Ge , Y. Li , Y. Qin , H. Fan , Y. Lv , X. Du , Y. Hu , Z. Liu","doi":"10.1016/S1556-0864(25)00225-4","DOIUrl":"10.1016/S1556-0864(25)00225-4","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 3","pages":"Page S30"},"PeriodicalIF":21.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
7MO: A phase II trial of tobemstomig (tobe) + platinum-based chemotherapy (chemo) vs pembrolizumab (pembro) + chemo in patients (pts) with untreated locally advanced or metastatic non-small cell lung cancer (NSCLC) 7MO：在未经治疗的局部晚期或转移性非小细胞肺癌（NSCLC）患者中，托布单抗(tobe) +铂基化疗（chemo）与派姆单抗(pembrolizumab) +化疗（pembrolizumab）的II期试验
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2025-03-01 DOI: 10.1016/S1556-0864(25)00202-3
E. Nadal , A. Rittmeyer , F. De Marinis , D.H. Lee , S. Gadgeel , N. Vilariño , E. Bria , S. Arulananda , E.H. Cronenberg , V. Antic , E. Bennett , Y. Hu , K. Madden-Raja , P. Williams , H. Prizant , S. Popat
{"title":"7MO: A phase II trial of tobemstomig (tobe) + platinum-based chemotherapy (chemo) vs pembrolizumab (pembro) + chemo in patients (pts) with untreated locally advanced or metastatic non-small cell lung cancer (NSCLC)","authors":"E. Nadal , A. Rittmeyer , F. De Marinis , D.H. Lee , S. Gadgeel , N. Vilariño , E. Bria , S. Arulananda , E.H. Cronenberg , V. Antic , E. Bennett , Y. Hu , K. Madden-Raja , P. Williams , H. Prizant , S. Popat","doi":"10.1016/S1556-0864(25)00202-3","DOIUrl":"10.1016/S1556-0864(25)00202-3","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 3","pages":"Pages S11-S12"},"PeriodicalIF":21.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
71P: FIN-EGFRprint: A retrospective observational study to investigate treatments and outcomes in patients with epidermal growth factor receptor-mutated (EGFRm) advanced non-small cell lung cancer (aNSCLC) in Finland 71P: FIN-EGFRprint：芬兰一项回顾性观察性研究，探讨表皮生长因子受体突变（EGFRm）晚期非小细胞肺癌（aNSCLC）患者的治疗和预后
IF 21 1区 医学
Journal of Thoracic Oncology Pub Date : 2025-03-01 DOI: 10.1016/S1556-0864(25)00266-7
A. Knuuttila , L. Nurmi , P. Vänni , J. Edwards , M. Ekblom , I. Luccarini , M. Silvoniemi
{"title":"71P: FIN-EGFRprint: A retrospective observational study to investigate treatments and outcomes in patients with epidermal growth factor receptor-mutated (EGFRm) advanced non-small cell lung cancer (aNSCLC) in Finland","authors":"A. Knuuttila , L. Nurmi , P. Vänni , J. Edwards , M. Ekblom , I. Luccarini , M. Silvoniemi","doi":"10.1016/S1556-0864(25)00266-7","DOIUrl":"10.1016/S1556-0864(25)00266-7","url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 3","pages":"Page S54"},"PeriodicalIF":21.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信